May 25, 2022--Researched by Industrial Info Resources (Sugar Land, Texas)--While promising to keep the availability of essential drugs needed by Russian citizens, major drug companies have responded to the Ukraine invasion from a financial position. The responses all seem to center on cancelling or halting planned capital investments, along with discontinuation of clinical trials in Russia. Nobody currently in a clinical trial will be abandoned, but no new studies will be started. Companies featured: Pfizer Incorporated, (NYSE:PFE) (New York, New York), Novartis International AG (NYSE:NVS), Novo Nordisk A/S (NYSE:NVO), Eli Lilly (NYSE:LLY)
(All Fields Required)
Site-wide Scheduled Maintenance for April 12, 2025, between 9 A.M. - 9 P.M. CST. During this time, all services will be unavailable periodically throughout the scheduled maintenance window.
×For More Info!
